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Abstract
Background: Evidence suggests that the presence of peptidyl arginine deiminase type 4 (PAD4) antibodies is
associated with radiographic-severity rheumatoid arthritis (RA) among Caucasian patients. The presence of anti-
PAD4 antibodies that were cross-reactivity against PAD3 was associated with more aggressive erosive disease
(compared with the presence of anti-PAD4 antibodies without anti-PAD3 crossreactivity) in Caucasian RA patients.
The objectives of this study were to determine the prevalence of serum anti-PAD4 and anti-PAD4/PAD3 cross-
reactive autoantibodies in African Americans with RA and whether these antibodies associate with radiographic
severity and radiographic progression.
Methods: Serum anti-PAD4 and anti-PAD4/PAD3 antibodies were measured by immunoprecipitation, and the
temporal trends in titers were analyzed. We compared total radiographic scores among anti-PAD4-positive, anti-
PAD4/PAD3-positive, and anti-PAD4-negative patients and used a zero-inflated negative binomial model to
determine associations between radiographic severity and antibody status. Logistic regression was used to analyze
radiographic progression.
Results: Of 192 African-American patients with RA, 73 % were anti-citrullinated peptide/protein antibody (ACPA)-
positive, 46 out of 192 (24 %) of whom had serum anti-PAD4 antibodies. Median (interquartile range) total Sharp
van der Heijde radiographic scores were 2 (1–97.5) in ACPA-positive patients and 0 (0–3) in ACPA-negative patients
(P < 0.001). Of the 46 anti-PAD4-positive patients, 20 had anti-PAD4 antibodies that cross-reacted with PAD3. In
patients with early RA, anti-PAD4 and anti-PAD4/PAD3 antibody titers increased over time (P = 0.006, P = 0.001,
respectively). Median (interquartile range) total radiographic scores were higher for anti-PAD4-positive than for
anti-PAD4-negative patients (3 (1–115) versus 2 (0–11), respectively; P = 0.005). Median (interquartile range) total
radiographic score for anti-PAD4/PAD3-positive patients was 76 (3–117) (P < 0.001) versus anti-PAD4-negative
patients. Only anti-PAD4/PAD3 antibodies associated with radiographic severity (incidence rate ratio = 2.81; 95 %
confidence interval 1.23, 6.43).
Conclusion: This analysis suggests that autoantibodies against PAD4 and PAD3 proteins may serve as biomarkers
for identifying African-American patients with RA and higher radiographic severity.
Keywords: Anti-PAD4, Rheumatoid arthritis, Radiographic severity, African American
* Correspondence: inavarro@uabmc.edu
1University of Alabama at Birmingham, 510 20th Street South, Faculty Office
Tower 850, Birmingham, AL 35294-3408, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Navarro-Millán et al. Arthritis Research & Therapy  (2016) 18:241 
DOI 10.1186/s13075-016-1126-7
Background
Rheumatoid arthritis (RA) is an autoimmune inflamma-
tory arthritis characterized by the presence of serum
autoantibodies, including rheumatoid factor and anti-
citrullinated peptide/protein antibodies (ACPAs) [1].
Antibodies to citrulline-containing epitopes in a variety
of proteins, including enolase and filaggrin among
others, appear to be common (50–60 %) in RA and are
relatively specific (>95 %) for the disease [2, 3]. Citrulli-
nation, catalyzed by the peptidyl arginine deiminase en-
zymes (PADs), is a calcium-dependent posttranslational
process in which arginine residues are deiminated [4]. In
RA, type 4 PAD (PAD4, encoded by PADI4 on chromo-
some 1p) is preferentially expressed in hematopoietic
cells, contributes to the generation of ACPA-specific
substrates, and is also a target of disease-specific auto-
antibodies [4].
PAD4 has an essential role in RA disease severity and
predisposition, with population studies demonstrating
genetic associations of PADI4 with RA, particularly
among Asian populations [5]. Among the European
ancestry population, autoantibodies to the PAD4 protein
were reported to be 42 % sensitive and 99 % specific for
RA in a cross-sectional study, and to associate with
radiographic severity [6, 7]. A proportion of these anti-
PAD4 antibodies have been demonstrated to cross-react
with the related protein PAD3, in blocking studies [6].
Anti-PAD4/anti-PAD3 cross-reactivity has been associ-
ated with severity of erosive joint disease and interstitial
lung disease in RA patients of predominantly European
ancestry [6, 8]. Anti-PAD4/PAD3 cross-reactive anti-
bodies are important in the pathogenesis of RA in that
they markedly increase the catalytic efficiency of PAD4
by decreasing its requirement for calcium to be active.
The presence of serum anti-PAD4/PAD3 antibodies
might thus help to identify RA patients who may benefit
from aggressive therapy.
The titers of anti-PAD4 autoantibodies were previously
analyzed cross-sectionally in non-African populations [6,
8, 9], and studies have determined the prevalence of
anti-PAD4 antibodies in established RA to be between
35 and 45 % [7, 10–12]. The prevalence of these
antibodies in the prediagnosis and postdiagnosis time
periods has been reported to be 18 % and 26 %,
respectively, which suggests that the development of
these antibodies occurs mainly over time [10]. Informa-
tion about how these titers change over time may also
facilitate determination of the pathophysiologic effect
these antibodies have on PAD4 that can subsequently
lead to aggressive disease. One study previously revealed
that the anti-PAD4 antibodies remain stable over time
after treatment with anti-tumor necrosis factor agents
[13]. However, the temporal trend in titers of anti-
PAD4/PAD3 cross-reactive antibodies has not been
analyzed, but is important because of the higher radio-
graphic severity described with these cross-reactive
antibodies [8].
Importantly, these autoantibodies have been studied
in detail in RA patients of European ancestry and in
Native Americans with RA [8, 9], but not in patients of
African-American ethnicity. It remains unknown
whether these antibodies are highly prevalent among
African Americans, and whether their presence is asso-
ciated with erosive disease in the same way it is among
patients of other ethnicities [6, 9]. The strong associ-
ation of the HLA-DRB1 locus with ACPA-positive RA
provides a rationale for examining the anti-PAD4 re-
sponse in African Americans with RA [14]. Notably, we
have recently shown subtle differences in the association
of HLA-DRB1 alleles with RA in African Americans
[15]. Furthermore, not all non-MHC region risk loci
identified in European or Asian RA populations are
shared with RA in persons of African ancestry, further
justifying the need for research on African Americans
with RA [16]. The objectives of this study are therefore:
to determine the prevalence of serum anti-PAD4 anti-
bodies (including anti-PAD4/PAD3 cross-reactive anti-
bodies) in African Americans with RA; to describe the
temporal changes in anti-PAD4 and anti-PAD4/PAD3
cross-reactive antibody titers; and to compare the radio-
graphic score and radiographic progression of anti-
PAD4-positive and anti-PAD4/PAD3-positive African-




In all, 192 participants in the Consortium for the Longi-
tudinal Evaluation of African Americans with Early
Rheumatoid Arthritis (CLEAR) Registry were included
in this study (Fig. 1). This group of patients has been the
subject of multiple reports, with radiographic findings
described previously [17]. The CLEAR Registry enrolled
patients with RA from 2000 to 2006 (CLEAR I) and
from 2006 to 2012 (CLEAR II) as defined by the revised
1987 American College of Rheumatology (ACR) criteria
[18], age ≥ 19 years, and self-defining as African American.
CLEAR I was a longitudinal registry enrolling African
Americans with early RA (disease duration < 2 years at the
time of enrollment) with comprehensive demographic,
clinical, and radiographic data at baseline (time of enroll-
ment in the cohort) and approximately 36 months from
disease onset. CLEAR II enrolled African Americans
with RA (without limits of disease duration) at a one-
time visit (cross-sectional approach). Subjects enrolled
in CLEAR I were not eligible for enrollment in CLEAR
II, so there is no overlap between the patients in
CLEAR I and CLEAR II.
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Variables
Demographic data, smoking status, medication use, and
the number of swollen and tender joints were collected
and assessed during the enrollment and follow-up visits.
ACPA (IgG) titers were measured in baseline serum, as
reported previously [19], using a commercially available
second-generation (anti-cyclic citrullinated peptide 2
(anti-CCP2)) enzyme-linked immunosorbent assay (ELISA)
kit (Diastat; Axis-Shield Diagnostics, Dundee, UK) using a
cutoff value for positivity of ≥5 IU/ml.
CLEAR I patients had radiographs of hands/wrists
(posteroanterior views) and feet (anteroposterior views)
at baseline (<2 years of disease duration) and approxi-
mately 36 months from disease onset. CLEAR II patients
had radiographs at the time of the single-study visit.
Radiographic scores were assessed using the modified
Sharp/van der Heidje score (total radiographic score =
total bone erosions and joint space narrowing) as de-
scribed previously [20].
CLEAR I was an early RA cohort established in 2000.
At that time, the use of biologic agents was in the early
stages and the majority of the patients in this cohort
were on methotrexate without biologic agents. Examin-
ation of the contribution of several variables such as
age, gender, or medication use revealed these were not
significantly associated with radiographic severity or
progression in bivariate analysis; hence these variables
were not included in the multivariable model. C-reactive
protein (CRP) was not included in the multivariable model
because measurements were available only at a limited
number of time points and thus did not substantively aid
the assessment of disease activity over the study period.
Exposure and comparator
The main exposure of interest was the presence of anti-
PAD4 antibodies and anti-PAD4/PAD3 cross-reactive
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Fig. 1 Blood samples and radiographs of patients with RA from the CLEAR I and CLEAR II cohorts. CLEAR I is a longitudinal registry of African-
American patients with early RA. CLEAR II is a cross-sectional registry of African-American patients with established RA. CLEAR Consortium for
the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis
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Autoantibody-detection assays
The presence of anti-PAD4 only antibodies and anti-
PAD4/PAD3 cross-reactive antibodies was determined
by immunoprecipitation as described previously [6]. To
detect these antibodies we employed a two-tier strategy
to first identify all patients in the cohort who had circu-
lating anti-PAD4 antibodies, and then test the anti-
PAD4-positive patients for cross-reactivity to PAD3.
Briefly, 1 μl of serum was incubated with in-vitro tran-
scribed and translated S35-labeled PAD4 protein for
1 hour at 4 °C in NP-40 lysis buffer/0.2 % bovine serum
albumin. Protein A agarose beads were then added to
immunoprecipitate antigen–antibody complexes. After
washes with NP-40 lysis buffer, samples were boiled in
SDS gel buffer and resolved by SDS-PAGE. Immunopre-
cipitated S35-labeled PAD4 was visualized by radiography
and quantified by densitometry. The densitometry values
were normalized to a serum with known high-titer anti-
PAD4 autoantibodies, and serum values with normalized
anti-PAD4 IU ≥ 0.02 were considered positive. Anti-PAD4
antibody-positive patients were further screened for anti-
body cross-reactivity to S35-labeled PAD3. Anti-PAD3
antibody immunoprecipitation was performed as already
described, and samples with normalized anti-PAD3 anti-
body IU ≥ 0.01 were considered positive. Serum samples
with anti-PAD3 or anti-PAD4 antibody IU > 0.2 were
considered medium to high titer, and those samples
with IU < 0.2 were considered low titer.
Outcome measures
The main outcome measures were total radiographic
score (total score at baseline analyzed cross-sectionally
for CLEAR I and CLEAR II combined) and radiographic
progression (analyzed only for CLEAR I). For the cross-
sectional analysis, radiographs were categorized as having
any damage (total radiographic score > 0) or no damage
(total radiographic score = 0). Overall progression of
radiographic scores in CLEAR I was defined by any unit
increase in the total radiographic score using the modified
Sharp/van der Heijde score divided by the time elapsed
between the enrollment radiographs to those obtained at
the 36-month disease duration visit.
A total of 81 CLEAR I patients were analyzed for radio-
graphic progression. This outcome was dichotomized as
no radiographic progression or any radiographic progres-
sion (total radiographic score of 0 or >0, respectively).
Statistical analysis
We calculated the prevalence of anti-PAD4 and anti-
PAD4/PAD3 antibodies at the time of enrollment in
CLEAR. We described the trends (changes from a posi-
tive titer to a negative titer status, and vice versa) of
anti-PAD4 and anti-PAD4/anti-PAD3 cross-reactive
antibody titers from baseline to 36-month disease
duration visit using the CLEAR I registry. We also de-
scribed the relationship and correlation of these titers
with RA disease duration. The nonparametric Wilcoxon
signed rank test was used to determine whether the
changes in these titers were different from 0.
We determined the proportion of patients with radio-
graphic damage (categorical measure) among both co-
horts combined (N = 192) and among those who were
anti-PAD4-positive, anti-PAD4/PAD3-positive, or anti-
PAD4-negative. We compared radiographic scores in
anti-PAD4-positive and anti-PAD4-negative patients; in
anti-PAD4/PAD3-positive and anti-PAD4-negative pa-
tients; and in anti-PAD4/PAD3-positive and anti-PAD4-
positive patients. Categorical measures were compared
using Fisher’s exact tests. Total radiographic scores (con-
tinuous measure) were analyzed by the nonparametric
Wilcoxon rank sum test, where appropriate.
Because radiographic scores are a count, and given the
large number of total radiographic scores of 0, we used
zero-inflated negative binomial models to determine the
association between anti-PAD4 positivity or anti-PAD4/
PAD3 positivity with higher radiographic scores (cross-
sectional analysis). Results of these models are reported
as the incidence rate ratio (IRR) [21]. 100 % of patients
who were anti-PAD3-positive were also anti-PAD4-
positive; and 91 % of patients who were anti-PAD4-
positive were also ACPA-positive. Thus, to avoid issues
with collinearity, the effects of ACPA, anti-PAD4, and
anti-PAD4/PAD3 antibody positivity were each evaluated
in separate models.
To evaluate radiographic progression, we used total
radiographic scores from baseline and from the subse-
quent visit in CLEAR 1 only. We performed descriptive
statistics for CLEAR 1 data prior to building the multi-
variable logistic regression models used to describe the
association between ACPA, anti-PAD4, or anti-PAD4/
PAD3 positivity with radiographic progression. The out-
come was modeled as change >0 versus change of 0 (no
change) in total radiographic score.
Results
There were 192 patients, 146 were anti-PAD4 antibody-
negative and 46 were anti-PAD4 antibody-positive. The
mean age of patients was 55 years, mean disease dur-
ation was 8 years (for CLEAR I and CLEAR II com-
bined), 86 % of patients were female, and 73 % of
patients were ACPA-positive (Table 1). Figure 1 shows
the flow diagram for the population of this study. The
prevalence of anti-PAD4 antibodies at the time of enroll-
ment in CLEAR was 24 % (N = 46), and 91 % of patients
who were anti-PAD4-positive were also ACPA-positive.
The prevalence of anti-PAD4/PAD3 was 10 % (N = 20).
Of the anti-PAD4-positive patients (N = 46), 83 % had
radiographic damage (total radiographic score > 0) at
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baseline, compared with 63 % in the anti-PAD4-negative
group (N = 146; P = 0.02). Median (interquartile range
(IQR)) radiographic scores for the anti-PAD4-positive
(N = 46) and anti-PAD4-negative (N = 146) patients were
3 (1–115) versus 2 (0–11), respectively (P = 0.005).
RA disease duration was longer among patients who
were positive for anti-PAD4 antibodies only (N = 26) and
those with cross-reactive anti-PAD4/PAD3 antibodies (N =
20) than in patients who were negative for either of these
antibodies (N = 146) (Table 1). The median (IQR) radio-
graphic score for the anti-PAD4/PAD3-positive patients
(N = 20) was 76 (3–117), which was significantly different
from the total radiographic score of the anti-PAD4-negative
patients (N = 146) (P < 0.001) (Table 1). The median (IQR)
total radiographic score for patients only positive for anti-
PAD4 antibodies (N = 26) was 2 (1–104), which was not
statistically different from those with anti-PAD4/PAD3
cross-reactive antibodies (N = 20) (P = 0.073) (Table 1).
Patients enrolled in CLEAR I, but not those enrolled
in CLEAR II, had available longitudinal samples which
allowed characterization of trends of anti-PAD4 and
anti-PAD4/PAD3 antibodies over time. Only patients
who were anti-PAD4-positive (≥0.02 anti-PAD4 antibody
IU) at any time in the initial screen (N = 21) were
included in this analysis. During the 36 months of dis-
ease, four patients seroconverted to anti-PAD4 positivity,
with three of the four patients developing anti-PAD3
cross-reactive antibodies. Of the nine patients with low-
titer antibodies against only PAD4 at baseline, four (44 %)
became negative, three (33 %) remained low titer, and two
(22 %) developed high-titer anti-PAD4 antibodies over
36 months. All eight patients who had high-titer anti-
PAD4 antibodies at baseline remained high titer at
36 months of disease, with seven of eight demonstrating
an increase in relative antibody titer. Of these eight
patients, two had anti-PAD4 antibodies, whereas six had
anti-PAD4/PAD3 cross-reactive antibodies for which the
titer also increased over the 36-month period. In patients
with early RA, both the overall anti-PAD4 and the anti-
PAD4/PAD4 antibody titers significantly increased over
time (P = 0.006 and P = 0.001, respectively) (Fig. 2a, b).
We performed separate analyses of radiographic severity
in CLEAR I and CLEAR II, and found that the only sig-
nificant variable was disease duration (data not shown).
We then proceeded to combine the data of both cohorts
to improve the power. Table 2 presents the results of the
zero-inflated negative binomial models used to assess the
relationship of these antibodies with higher radiographic











Demographic and RA-related variable (N = 192) (N = 146) (N = 26) (N = 20) P4 vs P0 XR vs P0 XR vs P4
Age (years), mean (SD) 55 (12.2) 54 (12.1) 55 (13.9) 59 (8.6) 0.755 0.077 0.288
Female, % 86 85 96 80 0.207 0.523 0.151
Disease duration (years), mean (SD) 8.1 (10.8) 7.2 (10.5) 10.4 (11.2) 12.8 (11.6) 0.029 0.004 0.386
+anti-CCP, % 73 67 88 95 0.035 0.008 0.622
Total radiographic score,a median (IQR) 2 (0–57) 2 (0–11) 2 (1–104) 76 (3–117) 0.231 0.001 0.082
CRP (mg/dl) 14 (36) 16 (40) 8 (10) 9 (13) 1.000 0.391 0.598
Smoking, % 0.387 0.183 0.852
Current 56 33 19 15
Former 45 21 27 35
Never 92 46 54 50
Medications, %
Methotrexate 63 63 69 85 0.660 0.080 0.302
HCQ 29 29 34 20 0.645 0.441 0.336
Sulfasalazine 8 8 8 5 1.000 1.000 1.000
Leflunomide 5 5 0 5 0.600 1.000 0.435
Infliximab 4 4 0 10 0.593 0.248 0.184
Etanercept 4 4 4 10 1.000 0.248 0.572
Categorical variables were tested using Fisher’s exact tests, and continuous variables were tested using Wilcoxon rank sum tests
aTotal joint erosion and joint space narrowing
CLEAR Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis, RA rheumatoid arthritis, PAD peptidyl arginine deiminase
enzyme, CRP C-reactive protein, HCQ hydroxychloroquine, IQR interquartile range
P values less than 0.05 are shown in bold
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scores. The association with higher radiographic scores
detected in univariate analysis of anti-PAD4/PAD3 and
ACPA positivity persisted after multivariable adjustment
(Table 2). Results of the multivariable adjustment showed
that anti-PAD4/PAD3 cross-reactive antibodies associated
with higher radiographic scores with an IRR of 2.63 (95 %
confidence interval (CI) 1.16, 5.95; P = 0.001), whereas anti-
PAD4 antibodies alone did not associate with higher radio-
graphic scores. Other variables included in the multivari-
able model that associated with higher radiographic score
were disease duration and ACPA positivity. Radio-
graphic severity reached statistical significance when
former smokers were compared with the group who
never smoked. This statistical significance was observed
only in the anti-PAD4/PAD3 cross-reactive antibodies
model (Table 2).
A total of 81 radiographic scores were used in the ana-
lysis of the longitudinal data. Additional file 1: Table S1
presents the characteristics of the CLEAR I cohort used
for analysis of radiographic progression. Table 3 presents
the results of radiographic progression between baseline
and 36-month disease duration visit for the CLEAR I pa-
tients. Neither anti-PAD4 nor anti-PAD4/PAD3 positiv-
ity was associated with radiographic progression; the
baseline radiographic score was the only factor associ-
ated with radiographic progression.
Discussion
Our study is the first assessment of anti-PAD4 and anti-
PAD4/PAD3 cross-reactive antibodies in African-
American patients with both early and established RA.
The prevalence of anti-PAD4 antibodies in these
African-American patients with RA was similar to that
reported for patients of European ancestry with RA [4,
6, 8]. We found that cross-reactive anti-PAD4/PAD3
antibodies associated with higher radiographic scores,
whereas anti-PAD4 antibodies without anti-PAD3 re-
activity did not. Furthermore, anti-PAD4 and anti-
PAD4/PAD3 antibody titers increased at the subsequent
visit among patients with early RA. Neither anti-PAD4
nor anti-PAD4/PAD3 antibodies were significantly asso-
ciated with radiographic progression. However, this may
be due to the preponderance of normal radiographs at
baseline, the small sample size (N = 81), the early stage
of the disease (<2 years’ disease duration at enrollment),
and/or the relatively short time between baseline and
follow-up radiographs. The finding of the importance of
disease duration in our model underscores the likelihood
of this explanation. In addition, previous studies that an-
alyzed the prevalence and association of anti-PAD4 and
anti-PAD4/PAD3 antibodies with radiographic progres-
sion had longer disease duration (mean disease duration
of 8–21 years) [6, 8].
PAD4 is one of the five subclasses of PAD enzymes that
catalyze the conversion of arginine residues to citrulline
residues. This modification has been implicated in changes
to the structure and function of the targeted protein
described to break tolerance and trigger autoimmunity
[22, 23]. A subset of antibodies against PAD4 can increase
calcium sensitivity that leads to activation of this enzyme
and a subsequent increase in citrullination [6]. The origin
of autoantibodies against PADs remains unknown, but high
levels of PAD4 in the lungs and periodontium that occur in
smokers implicate the potential importance of these sites
[24]. Additionally, cross-reactive anti-PAD4/PAD3 anti-
bodies have been associated with the development of inter-
stitial lung disease among patients with RA [8, 23, 24],
especially in patients with a history of smoking [8].
Fig. 2 Changes in titers of anti-PAD4 antibodies and anti-PAD4/PAD3
cross-reactive antibodies among CLEAR I RA patients. Only patients
who were anti-PAD4-positive (≥0.02 anti-PAD4 antibody IU) at any
time (baseline or 36-month disease duration visit) were included
(N = 21). Relative titers of anti-PAD4 antibodies (a) and of anti-PAD4
antibodies that cross-react with PAD3 (b) at baseline and 36 months of
actual RA disease duration determined by densitometry. Red horizontal
line, cutoff between low and high antibody titer. Changes in antibody
levels from baseline to 36-month disease duration visit were tested
using the Wilcoxon signed rank test, P < 0.05 considered significant.
PAD peptidyl arginine deiminase enzyme (Color figure online)
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RA patients who smoke have been reported to have a
higher risk for development of radiographic erosions
[25]. We did not observe an association between smok-
ing and radiographic severity and radiographic progres-
sion. However, the point estimates showed an increased
risk for radiographic severity and a trend towards an as-
sociation in the cross-sectional analysis. These differ-
ences were likely in part due to the small sample size in
our study compared with larger epidemiologic studies.
Our study is the first to describe the pattern of anti-
PAD4/PAD3 cross-reactive antibody titers over time, an
aspect that has only thus far been described cross-
sectionally [6, 8, 9]. One small study did analyze anti-
PAD4 antibodies titers, but not the PAD3 cross-reactive
subset, longitudinally in a predominantly Caucasian
population with a mean RA disease duration of 11.5 years
[13]. In that study, the anti-PAD4 antibodies were stable
over 1 year of follow up. Unlike previously reports, the
mean levels of anti-PAD4 antibodies and anti-PAD4/
PAD3 antibody titers did increase significantly over a
mean period of 22 months of follow up in our African-
American cohort of patients with early RA (mean disease
duration at enrollment of 15 months). In our cross-
sectional model, anti-PAD4/PAD3 antibodies significantly
associated with radiographic severity. This association
persisted even after controlling for disease duration, which
was the only variable associated with radiographic severity
when the models for radiographic severity were run separ-
ately for each cohort. This suggests that a significant in-
crease in radiographic severity may, albeit relatively small,
occur when these antibodies target both PAD3 and PAD4;
and that these antibodies are a risk factor for disease sever-
ity which accumulates over time. It has been reported that
the development of anti-PAD4 antibodies occurs mainly in
long-standing RA rather than in early RA. In our cohort,
however, the majority of the patients positive for these anti-
bodies had these antibodies even within the first 2 years of
disease onset (CLEAR I data only).
It is possible that PAD4 (and therefore anti-PAD4
antibodies) has an effect on cytokine expression that
influences disease activity. Indeed, PAD4 inhibition
significantly attenuated the expression of neutrophil
chemotactic proinflammatory cytokines (macrophage
inflammatory protein-2 and keratinocyte-derived cyto-
kine) in response to renal ischemia/reperfusion injury
in a murine model [26]. This information is important
Table 2 Unadjusted and adjusted zero-inflated negative binomial models to evaluate the association of anti-PAD4 or anti-PAD4/PAD3
positivity with total radiographic scores for CLEAR I and CLEAR II patients at baseline (cross-sectional analysis) (N = 192)
Predictor/variable Each variable combined with disease duration (BL)
(IRR; 95 % CI)
Multivariablea (BL)




Anti-CCP 3.87 (1.90, 7.89) 4.48 (2.15, 9.36) <0.001
RA disease duration (per 6 months) 1.05 (1.03, 1.07) 1.06 (1.04, 1.08) <0.001
Smoking (reference to never smoker)
Current 1.36 (0.73, 2.50) 1.22 (0.67, 2.25) 0.517
Former 0.75 (0.39, 1.44) 0.57 (0.29, 1.20) 0.093
Anti-PAD4 model
Anti-PAD4 1.25 (0.71, 2.22) 1.76 (0.89, 3.46) 0.102
RA disease duration (per 6 months) 1.05 (1.03, 1.07) 1.05 (1.03, 1.07) <0.001
Smoking (reference to never smoker)
Current 1.36 (0.73, 2.50) 1.40 (0.76, 2.58) 0.284
Former 0.75 (0.39, 1.44) 0.54 (0.25, 1.15) 0.110
Anti-PAD4/PAD3 model
Anti-PAD4/PAD3 cross-reactivity 1.88 (0.88, 4.03) 2.63 (1.16, 5.95) 0.020
RA disease duration (per 6 months) 1.05 (1.03, 1.07) 1.06 (1.04, 1.08) <0.001
Smoking (reference to never smoker)
Current 1.36 (0.73, 2.50) 1.30 (0.71, 2.38) 0.403
Former 0.75 (0.39, 1.44) 0.50 (0.25, 1.00) 0.049
RA medication and age were not significantly associated with the outcome in the bivariable model and therefore were not included in the multivariable model
aMultivariable model adjusted for all the variables included in the table
PAD peptidyl arginine deiminase enzyme, CLEAR Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis, BL baseline
data, IRR incidence rate ratio, CI confidence interval, RA rheumatoid arthritis
P values less than 0.05 are shown in bold
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because it suggests these antibodies may not only serve
as a marker of disease severity but also have diagnostic
value and could be a target of future therapies for RA.
This study has several strengths, including being the
first analysis of anti-PAD4 and anti-PAD4/PAD3 cross-
reactive antibodies in a well-characterized cohort of Af-
rican- American patients with RA. This study also de-
scribes the longitudinal pattern of anti-PAD4 and anti-
PAD4/PAD3 antibody titers in patients with early RA,
the former of which has only been studied previously in
patients with established RA [13]. A recent study of 39
patients with RA also found that anti-PAD4/PAD3
cross-reactive antibodies were strongly associated with
joint erosions [27]. Limitations of this study include the
relatively small sample size and that the longitudinal
data were derived predominantly from patients with
early RA with normal radiographs. We speculate that
the lack of association between anti-PAD4 and anti-
PAD4/PAD3 antibodies with radiographic progression in
CLEAR I is mainly due to the small sample size and less
likely due to a lack of contribution of these antibodies to
more severe and aggressive RA. Notably, the effect of
biologics on radiographic severity and progression was
limited in this study because these medications had just
been approved when the CLEAR Registry was estab-
lished. This study could not assess accurately the radio-
graphic effect of disease activity because the levels of
several important variables used to measure disease ac-
tivity, such as CRP, were not collected consistently, and
disease activity instruments, such as the Disease Activity
Score in 28 joints (DAS28), was not yet the most com-
monly used tool for disease activity.
Conclusion
This is the largest and first study to analyze the relation-
ship between radiographic severity and anti-PAD4 and
anti-PAD4/PAD3 antibodies in African Americans. The
prevalence of these antibodies was similar to that ob-
served in cohorts of predominantly Caucasian or Native-
American patients with RA. This analysis suggests that
autoantibodies against PAD4 and PAD3 proteins may
serve as biomarkers for identifying African-American
patients with RA and higher radiographic severity. Fu-
ture studies with larger cohorts are needed to accurately
Table 3 Multivariable logistic regression models evaluating change in radiographic score (change of 0 or >0) between baseline (< 2
years disease duration) and approximately 36-month disease duration visit in CLEAR I patients (N = 81)
Predictor/variable Odds ratio (adjusted)a 95 % CI P value
Multivariable model 1: anti-CCP
Anti-CCP 2.73 (0.83, 9.0) 0.099
RA disease duration (per 6 months) 0.90 (0.58, 1.38) 0.618
Baseline radiographic score (0 referent to >0) 3.91 (1.38, 11.03) 0.010
Smoking (reference to never smoker)
Current 0.80 (0.25, 2.49) 0.695
Former 0.67 (0.18, 2.45) 0.546
Multivariable model 2: anti-PAD4
Anti-PAD4 0.59 (0.14, 2.51) 0.609
RA disease duration (per 6 months) 0.87 (0.57, 1.33) 0.526
Baseline radiographic score (0 referent to >0) 5.41 (1.97, 14.86) 0.001
Smoking (reference to never smoker)
Current 0.65 (0.21, 2.10) 0.478
Former 0.60 (0.17, 2.20) 0.445
Multivariable model 3: anti-PAD4/PAD3
Anti-PAD4/PAD3 0.21 (0.02, 2.76) 0.235
RA disease duration (per 6 months) 0.87 (0.57, 1.35) 0.540
Baseline radiographic score (0 referent to >0) 6.36 (2.22, 18.20) <0.001
Smoking (reference to never smoker)
Current 0.55 (0.18, 1.78) 0.319
Former 0.51 (0.14, 1.89) 0.313
RA medication and age were not significantly associated with the outcome in the bivariable model and therefore were not included in the multivariable models
aAdjusted for all variables included in the table
CLEAR Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis, CI confidence interval, RA rheumatoid arthritis,
PAD peptidyl arginine deiminase enzyme
P values less than 0.05 are shown in bold
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determine whether anti-PAD4 or anti-PAD4/PAD3 anti-
body titers associate with radiographic progression.
Additional file
Additional file 1: Table S1. Characteristics of the CLEAR I patients used
to analyze radiographic progression (N = 81). (DOCX 14 kb)
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